The table below summarizes the most recent Vincerx Pharma insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Vincerx Pharma insider buys are important for investors to follow.

Date	Insider	Price	Amount
8-11-2023 Insider Buy	Alexander A. Seelenberger See Remarks	$0.95 CAGR »	$9,967.65 10,500 shares
8-10-2023 Insider Buy	Raquel E. Izumi See Remarks	$0.91 CAGR »	$14,934.21 16,476 shares
8-10-2023 Insider Buy	Tom C. Thomas See Remarks	$0.95 CAGR »	$4,750.00 5,000 shares
8-10-2023 Insider Buy	Ahmed Hamdy, M.D. See Remarks	$0.95 CAGR »	$21,161.42 22,300 shares
12-14-2022 Insider Buy	Tom C. Thomas See Remarks	$0.83 CAGR »	$5,810.00 7,000 shares
12-14-2022 Insider Buy	Ahmed Hamdy, M.D. Chief Executive Officer	$0.87 CAGR »	$30,538.37 35,280 shares
12-14-2022 Insider Buy	Raquel E. Izumi See Remarks	$0.88 CAGR »	$25,427.38 28,738 shares
8-25-2022 Insider Buy	Christopher P. Lowe Director	$1.65 CAGR »	$49,438.12 30,000 shares
6-27-2022 Insider Buy	Raquel E. Izumi See Remarks	$1.41 CAGR »	$56,312.00 40,000 shares
6-23-2022 Insider Buy	Ahmed Hamdy, M.D. Chief Executive Officer	$1.41 CAGR »	$34,136.52 24,200 shares
6-9-2022 Insider Buy	Laura I. Bushnell Director	$1.91 CAGR »	$28,624.50 15,000 shares
12-22-2021 Insider Buy	Tom C. Thomas See Remarks	$10.23 CAGR »	$10,230.00 1,000 shares
12-22-2021 Insider Buy	Alexander A. Seelenberger Chief Financial Officer	$10.34 CAGR »	$24,987.91 2,417 shares
12-22-2021 Insider Buy	Laura I. Bushnell Director	$10.48 CAGR »	$25,172.96 2,402 shares
12-23-2021 Insider Buy	Sooin Hwang Chief Business Officer	$10.00 CAGR »	$30,000.00 3,000 shares
6-29-2021 Insider Buy	Ahmed Hamdy, M.D. Chief Executive Officer	$12.77 CAGR »	$99,989.10 7,830 shares
6-30-2021 Insider Buy	Laura I. Bushnell Director	$12.94 CAGR »	$23,297.40 1,800 shares

Also See: Institutional Holders of VINC
Also See: SEC filings

Below we present the annualized performance delivered by Vincerx Pharma stock since 8-11-2023 (the date of the most recent insider purchase). The performance of the investment from the time Vincerx Pharma insider buying occurred is the ultimate test of whether insiders were right about VINC being a good buy.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	08/14/2023
End date:	04/26/2024
Start price/share:	$0.89
End price/share:	$0.73
Dividends collected/share:	$0.00
Total return:	-17.98%
Annualized Gain:	-25.63%
Starting investment:	$10,000.00
Ending investment:	$8,202.00
Years:	0.70

Vincerx Pharma Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Vincerx Pharma insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding VINC

VINC — Current Quote

Quotes delayed 20 minutes

Free VINC Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

VINC — Performance

More Insider Buying

Other companies seeing insider buying close in time to when the Vincerx Pharma Insider Buying occurred are:

Leslies Insider Buying
Sabre Insider Buying
Superior Group of Companies Insider Buying
Artesian Resources Insider Buying
TG Therapeutics Insider Buying
Skyward Specialty Insurance Group Insider Buying
LINKBANCORP Insider Buying
Sigilon Therapeutics Insider Buying
Royal Caribbean Group Insider Buying
AdaptHealth Insider Buying

Vincerx Pharma Insider Buying

Vincerx Pharma Insider Buying | www.HoldingsChannel.com